PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the AASLD

New digital pathology, quantitative picture evaluation and quantitative AI methodology for liver tissues is introduced for the steady evaluation of the histological phenotype(s) of fibrosis, together with severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid fashions, NASH rodent fashions, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021PRINCETON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) — PharmaNest is a digital pathology and synthetic intelligence firm that’s targeted on the growth and validation of novel requirements for quantification of the histological phenotype(s) of fibrosis and related histological options for drug discovery and growth. Launched in 2019, PharmaNest’s FibroNest™ multi-vendor Quantitative Image Analysis and Quantitative AI platform automates the quantification of fibrosis and illness exercise (Steatosis, Ballooning and Inflammation) for each non-alcoholic fatty liver illness (NAFLD) and non-alcoholic steatohepatitis (NASH), utilizing digital photos of stained tissues. It is a for-research-only-use venture at this time. As a multi-vendor platform, FibroNest is suitable with all types of digital picture codecs, together with typical digital pathology-stained slides (Picro Sirius Red, Trichrome or Antibody stains for fibrosis) acquired by each FDA-approved, digital pathology scanners and different digital microscopes. At the 2021 AASLD | The Liver Meeting Digital Experience™ (TLMdX), PharmaNest and its world-class educational and trade collaborators current outcomes that show the translational capabilities of FibroNest throughout the drug discovery and growth continuum together with: The quantification of the development of fibrosis in Human in-vitro 3D NASH tissue fashions and their response to Alk5 inhibitors and anti-TGB beta therapies – displaying the utility of the mixed applied sciences to speed up the discovery of novel anti-fibrotic compounds, in a collaboration with InSphero (Schlieren, Switzerland).The comparability of Whole Slide Digital Imaging and Two Photon (Second Harmonic Generation) digital imaging utilizing FibroNest™ to consider the anti-fibrotic and anti-steatotic results of FXR agonists in Leptin-deficient mice meals with high-fat diets (NASH mannequin), in a collaboration with Intercept, Inc. (New York, USA).The growth and validation of a extremely delicate, steady digital pathology rating, used to classify sufferers between NASH Fibrosis phases of F2 and F3, with a sensitivity and specificity efficiency of greater than 90%, in a collaboration with Virginia Commonwealth University (Richmond, USA), Bristol Myers Squibb (Princeton, USA) and University of California (San Diego, USA).The quantification of the histological phenotypes of fibrosis in LEAN and OBESE sufferers with NAFLD and F2 / F3 fibrosis, and the comparability of those phenotypes, in a collaboration with the Yokohama City University School of Medicine (Yokohama, Japan) and The Chinese University of Hong Kong (Hong Kong).The growth of a digital pathology rating to routinely classify F1 NASH sufferers into sub-stages, reminiscent of F1a, F1b and F1c, in a collaboration with Lipocine, Inc (Salt Lake City, USA) and University of California (San Diego, USA). In addition, a number of different communications at AASLD | TLMdX, 2021 will current the contribution of FibroNest’s Digital Pathology and Quantitative AI platform in the quantification of novel medicine investigated in Phase2b research, reminiscent of the LPCA 1144 Therapy (a collaboration with Lipocine, Inc., Salt Lake City, USA). These outcomes will likely be introduced at The Liver Meeting Digital Experience™ (TLMdX) 2021 at the following poster displays. Please contact PharmaNest to schedule one-on-one or group webinar displays. AASLD “Poster of Distinction”: #1704 – Is the histological phenotype of Fibrosis totally different between LEAN and OBESE NASH sufferers? Michihiro Iwaki (1), Li Chen (2), Mathieu Petitjean (2), Atsushi Nakajima (1), Vincent Wai-Sun Wong (3) – (1) Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Japan (2) PharmaNest Inc, Princeton, New Jersey, USA (3) Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.  #1601 – Evaluation of the multivendor efficiency of a novel histology-based fibrosis phenotypic composite rating and its correlation with NASH-CRN Fibrosis scores in sufferers with NASH Li Chen (1), Michael Lung (2), Cynthia Behling (3), Anthony Azzara (4), Diane Shevell (4), Arun J. Sanyal (5), Mathieu Petitjean (1) – (1) PharmaNest, Princeton, NJ, USA (2) Pacific Rim Pathology, San Diego, CA, USA (3) Department of Pediatrics University of California, San Diego, CA, USA (4) Bristol Myers Squibb, Princeton, NJ, USA (5) Virginia Commonwealth University, Richmond, VA, USA #LP41 – LPCN 1144 Therapy demonstrates Histologic Benefits in the Phase2 LiFT Study in NonAlcoholic Steatohepatitis (NASH) Subjects. Arun J Sanyal (1), Benjamin J Bruno (2), Kilyoung Kim (2), Shadi Mehraban (2), Kongnara Papangkorn (2), Anthony DelConte (2),(3), Nachiappan Chidambaram (2) and Mahesh V Patel (2), (1) Div of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA, (2) Lipocine Inc., Salt Lake City, UT, USA, (3) Department of Pharmaceutical/Healthcare Marketing, Saint Joseph’s University, Philadelphia, PA, USA #1908 – Digital Pathology Image Analysis Accurately Quantifies Anti-fibrotic and Anti-steatotic results of FXR Agonists Using Multiple Histological Methods. Li Chen (1), Mary Erickson (2), Luciano Adorini (2), Jonathan Roth (2), Mathieu Petitjean (1) – 1 PharmaNest, Princeton, USA, 2 Intercept Pharmaceuticals, San Diego, USA #1587 – Continuous staging of NASH Patients at low (F1) Fibrosis Severity: Evaluation of the efficiency of a novel histology-based fibrosis phenotypic composite rating and predictive AI instruments. Li Chen (1), Dmitry Fedorov (2), Mathieu Petitjean (1), Benjamin J. Bruno (3), Kilyoung Kim (3), Cynthia Behling (4), Anthony DelConte (5), Nachiappan Chidambaram (3)  – (1) PharmaNest Inc, Princeton, New Jersey, USA (2) ViQi Inc, Santa Barbara, California, USA (3) Lipocine Inc. Salt Lake City, Utah, USA (4) Pacific Rim Pathology, San Diego, CA, USA (5) Saint Joseph’s University, Philadelphia, PA, USA # 1183 – SB CCA.Mdr2-/-, a brand new mouse mannequin of Cholangiocarcinoma arising in the PSC-like settings of progressive biliary damage and fibrosis. Pinzhu Huang1, Guangyan Wei 1, Shuangshuang Zhao1, Disha Badlani1, Kahini Vaid1, Li Chen2, Mathieu Petitjean2, Xin Chen3, Gregory Gores4, Yury Popov1 – (1) Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, (2) PharmaNest, Inc, Princeton, NJ, (3) University of California, San Francisco, CA and (4) Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN #1362 – Evaluation of anti-fibrotic results of compounds in human 3D NASH mannequin utilizing phenotypic quantification of fibrosis digital pathology photos. Li Chen (1),Simon Strӧbel (2), Mathieu M. Petitjean (1), Eva Thoma (2), Radina Kostadinova (2) (1) PharmaNest, Princeton, NJ, USA (2) InSphero AG, Schlieren, Switzerland PharmaNest | Press contacts Dr. Mathieu M.  Petitjean CEO [email protected] Related Images Image 1: FibroNest Liver NASH Biopsy Quantitative Image Analysis FibroNest supplies Could-based Quantitative Image Analysis (NASH Liver Biopsy) and makes use of Quantitative AI to set up steady scores to stage illness severity. This content material was issued by means of the press launch distribution service at

FibroNest Liver NASH Biopsy Quantitative Image Analysis

Recommended For You